🚨 Pharma Exports at Risk Amid West Asia War!

India’s pharmaceutical exports are facing major disruption as the ongoing US-Israel–Iran conflict drives freight costs sharply higher.! According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), a complete halt in shipments to West Asia this month could wipe out ₹2,500–₹5,000 crore worth of exports. 📦 Why the disruption? • Freight surcharges have surged to $4,000–$8,000 per shipment • Higher insurance premiums and fuel costs • Longer shipping routes causing delays and logistical bottlenecks ⛽ The conflict has also pushed Brent Crude Oil prices up nearly 16%, rising from $72.48 (Feb 28) to around $84 per barrel. 🌍 Critical trade routes under pressure • Strait of Hormuz – Handles ~50% of India’s oil imports and ~80% of natural gas flows • Red Sea shipping lanes – Key route for pharma exports and API imports Any disruption on these routes could affect temperature-sensitive medicines and APIs, especially those requiring strict cold-chain logistics. 📊 Why West Asia matters for Indian pharma • Region contributes 5.5%+ of India’s $30B pharma exports • Exports to the region rose from $1.32B (FY21) to $1.75B (FY25) Key markets include: 🇦🇪 United Arab Emirates 🇸🇦 Saudi Arabia 🇴🇲 Oman 🇰🇼 Kuwait These countries rely heavily on affordable Indian generic medicines, making India a crucial supplier for the region. ⚠️ Industry Warning: Logistics pressure is rising at a pace not seen since the pandemic disruptions, and exporters are seeking government support and alternative shipping routes to maintain supply. 📉 Market Impact: Rising costs, inventory disruptions, and stretched working capital could pressure Indian pharma exporters in the near term.